Floatz logo

bay1093884

Hemophilia A

BayerPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

47 Active assets in the Hemophilia A cohort.

Asset / SponsorPhaseRating
Rurioctocog Alfa Pegol
Takeda
Phase 4BBB
bay94-9027
Bayer
Phase 4BBB
Emicizumab
Emory University
Phase 4BBB
Fitusiran
Sanofi
Phase 4BBB
Damoctocog Alfa Pegol
Bayer
Phase 4BBB

View all 50 →

Same molecule, other indications

bay1093884 is also rated in:

Hemophilia A and BDormant
CCC
Indicative ·
52 / 100
View asset →
Hemophilia BDormant
CC
Indicative ·
44 / 100
View asset →
HemophiliaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →